The much-awaited Sai Life Sciences IPO is set to finalize its basis of allotment on December 16, 2024. With a robust response during the bidding process, the Hyderabad-based pharma research company raised a total of ₹3,042.62 crore. Investors are eager to know their allotment status, GMP trends, and listing details. Here’s everything you need to know.
IPO Key Details
| Particulars | Details |
|---|---|
| IPO Dates | December 11-13, 2024 |
| Price Band | ₹522-549 per share |
| Lot Size | 27 shares and multiples thereafter |
| Total Issue Size | ₹3,042.62 crore |
| Fresh Issue | ₹950 crore |
| Offer-for-Sale (OFS) | 3,81,16,934 shares |
| Overall Subscription | 10.26 times |
| Listing Date | December 18, 2024 |
| Stock Exchanges | BSE and NSE |
Subscription Details
| Investor Category | Subscription |
|---|---|
| Qualified Institutional Buyers (QIBs) | 30.93 times |
| Non-Institutional Investors (NIIs) | 4.92 times |
| Retail Investors | 1.37 times |
Grey Market Premium (GMP)
- Current GMP: ₹60-65
- Expected Listing Gains: Around 11-12%, suggesting strong investor confidence.
- Trend: GMP rose from ₹40-45 on the last bidding day to its current levels.
Financial Highlights
| Period | Net Profit (₹ crore) | Revenue (₹ crore) |
|---|---|---|
| FY24 (March 2024) | ₹410.67 | ₹2,112.32 |
| Q1 FY25 (June 2024) | ₹112.84 | ₹620.45 |
Sai Life Sciences has shown strong financial performance, with profitability driven by demand for Contract Research, Development, and Manufacturing Organization (CRDMO) services.
Positive Factors and Concerns
Positives:
- Strong Demand:
- High demand for CRDMO services across markets in US, UK, Europe, and Japan.
- Profitability:
- Consistent financial growth with increasing margins.
- Tailored Solutions:
- Focused offerings for biotech firms and global pharma giants.
Concerns:
- High OFS Component:
- Significant portion of proceeds goes to selling shareholders.
- Debt Levels:
- Elevated debt levels may limit financial flexibility.
- Valuation:
- Rich valuations could pose risks for new investors.
How to Check Allotment Status
On BSE Website:
- Visit BSE IPO Allotment Portal.
- Select Equity under “Issue Type.”
- Choose Sai Life Sciences Limited from the dropdown.
- Enter Application Number and PAN ID.
- Click on “I am not a Robot” and hit Search.
On KFin Technologies Website:
- Visit KFin IPO Status Portal.
- Select the IPO from the dropdown.
- Enter your Application Number, Demat Account Number, or PAN ID.
- Choose ASBA or non-ASBA under “Application Type.”
- Fill in the captcha and click Submit.
Broker Recommendations
- Analysts are optimistic about Sai Life Sciences due to its:
- Strong market position in CRDMO.
- Tailored services for global pharma companies.
- Mixed views persist over rich valuations and high OFS.
Conclusion
The Sai Life Sciences IPO has garnered significant attention from investors, reflecting strong demand for its shares. With solid financial performance, increasing profitability, and robust subscription numbers, the IPO is expected to deliver moderate listing gains. Investors should monitor GMP trends and carefully review their allotment status as the shares are set to list on December 18, 2024.
Click here to know more.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Please consult a financial advisor before making investment decisions.
